In this episode, menopausal hormone therapy is not associated with breast cancer recurrence and mortality; pandemic-related screening declines may result in 'increased avoidable cancer deaths'; data on pertuzumab regimen in early breast cancer; and more. Read the full coverage here: Menopausal hormone therapy not associated with breast cancer recurrence, mortality Screening declines after pandemic onset may result in 'increased avoidable cancer deaths' Updated data show long-term benefit with pertuzumab regimen in early breast cancer Medical financial hardship linked to increased mortality risk among cancer survivors FDA grants priority review to Enhertu for HER2-low metastatic breast cancer References: Cold S, et al. J Natl Cancer Inst. 2022;doi:10.1093/jnci/djac112. Press Release Press Release Teglia F, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.2617. Yabroff KR, et al. J Natl Cancer Inst. 2022;doi:10.1093/jnci/djac044.

Ver todos los episodios